EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening for DAX1 / EWS‐FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma

Miwa Watanabe iD, Hiromichi Kosaka, Masamori Sugawara, Michihiro Maemoto, Yoko Ono, Takeshi Uemori, Ryota Shizu, Kouichi Yoshinari

Cancer Medicine · 2023

DOI: 10.1002/cam4.5741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Miwa Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Division, Kyowa Kirin Co., Ltd., Shizuoka, Japan. Hauptthemen laut MEDLINE: Sarcoma, Ewing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

EWS‐FLI1 is the most common oncogenic fusion protein in Ewing's sarcoma family tumors (ESFTs). DAX1, an orphan member of the nuclear receptor superfamily, is up‐regulated by EWS‐FLI1 and plays a key role in the transformed phenotype of ESFTs.

Methods

To discover a functional inhibitor of DAX1 and EWS‐FLI1, we screened small‐molecular inhibitors using a DAX1 reporter assay system.

Results

K‐234 and its derivatives, which were dihydroorotate dehydrogenase (DHODH) inhibitors, showed inhibitory effects in the reporter assay. K‐234 inhibited the growth of Ewing's sarcoma with various fusion types, and K‐234 derivatives altered the expression of EWS‐FLI1‐regulated genes. The DAX1 expression had no effect on the growth inhibitory effect of the K‐234 derivatives, while DHODH overexpression or uridine treatment attenuated their inhibitory effects, suggesting that inhibition by K‐234 derivatives occurs through DHODH inhibition. An in vivo study showed that a K‐234 derivative clearly inhibited tumor growth in an Ewing's sarcoma xenograft mouse model.

Conclusion

Taken together, the present results suggest that DHODH inhibitors can inhibit the function of DAX1/EWS‐FLI1 in ESFTs and might be a therapeutic agent with potent anti‐tumor activity for Ewing's sarcoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingHumansAnimalsMiceDihydroorotate DehydrogenaseProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSOncogene Proteins, FusionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

DAX1EWS-FLI1Ewing's sarcomadihydroorotate dehydrogenasenucleotide pool

Substanzen

EWS-FLI fusion proteinDihydroorotate DehydrogenaseProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Research and Development Division, Kyowa Kirin Co., Ltd., Shizuoka, Japan.
  • Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

ORCID-Profile: Miwa Watanabe

Zitieren

APA

Watanabe, M., Kosaka, H., Sugawara, M., Maemoto, M., Ono, Y., Uemori, T., Shizu, R., & Yoshinari, K. (2023). Screening for DAX1 / EWS‐FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma. Cancer Medicine. https://doi.org/10.1002/cam4.5741

Vancouver

Watanabe M, Kosaka H, Sugawara M, Maemoto M, Ono Y, Uemori T, et al. Screening for DAX1 / EWS‐FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma. Cancer Medicine. 2023. doi:10.1002/cam4.5741

BibTeX
@article{Watanabe2023,
  author = {Watanabe, Miwa and Kosaka, Hiromichi and Sugawara, Masamori and Maemoto, Michihiro and Ono, Yoko and Uemori, Takeshi and Shizu, Ryota and Yoshinari, Kouichi},
  title = {Screening for DAX1 / EWS‐FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5741}
}
Kostenlos starten →